Previously, it has been reported that acute exposure to GLP-1 did not significantly affect the metabolome 40 , nor bioenergetics of rodent -cells 15
Based on current clinical trial data, retatrutide produced the highest weight loss at 24.2 percent body weight over 48 weeks at the 12 mg dose

Tesamorelin vs Sermorelin: Choosing the Right Peptide for Your Research Choose Tesamorelin When: The primary research endpoint is visceral adipose tissue (VAT) reduction Rapid, measurable IGF-1 elevation is needed within a short protocol window Studying metabolic syndrome, abdominal obesity, or lipodystrophy models Extended protocol stability is required (tesamorelin resists enzymatic degradation better) Research budget supports a higher-cost compound for a shorter, intensive protocol Choose Sermorelin When: The focus is long-term endocrine system support and hormonal homeostasis Sleep architecture and recovery pathways are the primary study variables Anti-aging, collagen synthesis, or longevity markers are being investigated A physiological, pulsatile GH release pattern is required to preserve feedback loops Cost efficiency over a long-duration protocol is a consideration The comparison extends beyond just these two peptides
Yagoda, N
Once put into the body, whether as an injection or orally, GLP-1 antagonists mimic the actions of a hormone called glucagon-like peptide 1 (GLP-1)
One supplement that frequently sparks debate around timing is L-Carnitine